Compare TG Therapeutics Inc (TGTX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Warner Music Group Corp — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Warner Music Group Corp trades at $25.06 (market cap $13.12B). The key difference: Warner Music Group Corp is the larger of the two by market cap, and Warner Music Group Corp pays a 3.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WMG | |
|---|---|---|
Market Cap | $7.64B | $13.12B |
Sector | Health | Media |
52-Week High | $59.06 | $34.72 |
52-Week Low | $26.94 | $23.65 |
Enterprise Value | $7.84B | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Warner Music Group (WMG) trades at $24.78, down 6.17% in the past 24 hours, with a bearish technical signal and support near $23. Recent earnings show mixed results, with Q1 and Q2 2026 beats but Q3 and Q4 2025 misses. Revenue grew to $6.71B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, citing streaming growth and strategic renewals like the NetEase Cloud Music partnership announced July 16, 2026.
The outlook is cautiously optimistic, with strong analyst support and projected revenue growth to $7.3B in 2026. Risks include execution challenges amid leadership changes, competitive pressures, and market volatility. The current valuation at a P/E of 20.06 may appeal to growth-oriented investors, but near-term price weakness reflects earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
